author-photo

Ralf Brandt

Novartis

15

Papers

906

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model

2012 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (45)
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.

2011 Anti-Cancer Drugs
Show All
- Source
- Cite
- Save
Citations (53)
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

2011 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (135)
Abstract A7: The heparan sulfate mimetic PG545 as a monotherapy or in combination with the standard-of-care agents paclitaxel or carboplatin inhibits solid tumor progression in two murine models of ovarian cancer.

2011 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
A pharmaceutical composition for treating cancer comprising trypsinogen and / or chymotrypsinogen and an active agent selected from a selenium compound, vanilloid compound and a reducing agent cytoplasmic glycolysis

2010
Show All
- Source
- Cite
- Save
Citations (0)
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

2004 Cancer Research
Show All
- Source
- Cite
- Save
Citations (292)
Aus den Landesverbänden

2004
Show All
- Source
- Cite
- Save
Citations (0)
Effects of epithelial growth factor receptor (EGFR) kinase inhibitors on genetically reconstituted mouse mammary glands.

2003 Experimental and Toxicologic Pathology
Show All
- Source
- Cite
- Save
Citations (0)
Combination comprising an inhibitor of the signal transduction and an epothilone derivative

2002
Show All
- Source
- Cite
- Save
Citations (0)
Combinaison comprenant un agent pour diminuer l'activité du VEGF et un agent pour diminuer l'activité du EGF

2001
Show All
- Source
- Cite
- Save
Citations (0)